Clinical Trials Browser

Phase 1/2 × tazemetostat × Clear all

Prostatic Neoplasms

NCT03854474 2026-04-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Phase 1/2 Active not recruiting

49 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT04557956 2026-04-02

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Phase 1/2 Active not recruiting

16 enrolled

Dermatologic

Melanoma

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Genitourinary

Prostatic Neoplasms

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase 1/2 Active not recruiting

42 enrolled

Lymphoid

Lymphoma, Follicular

NCT02875548 2025-11-04

TRuST

Phase 1/2 Completed

58 enrolled

LymphoidOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Phase 1/2 Not yet recruiting

48 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

260 enrolled

Plasma cell

Multiple Myeloma

NCT02889523 2024-10-09

Epi-RCHOP

Phase 1/2 Active not recruiting

214 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Phase 1/2 Completed

400 enrolled 22 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT05604417 2023-07-07

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, Follicular

NCT05152459 2023-05-31

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, Follicular

Clinical Trials

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

CELLO-1

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

TRuST

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Epi-RCHOP

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

ARIA

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma